New Scientist Colab Podcasts – Détails, épisodes et analyse

About this episode SXSW London is the preeminent forum for the new ideas and leading thinkers who are sculpting the future. In this episode, we talk to Kat Sherling, head of conference at the event to explore the cultural and technological forces driving the agenda at this year’s festival and discover some of the speakers who will be there in June. This is a New Scientist CoLab production, sponsored by the SXSW London. Your host is Justin Mullins. Find out more about how we’re adapting to a rewired world with this New Scientist CoLab article : https://www.newscientist.com/article/2517346-can-humanity-find-a-place-in-the-rewired-world/ Learn more about your ad choices. Visit megaphone.fm/adchoices

The production of medicines is a high-stakes industry where efficiency and environmental impact often collide.  Given that the pharmaceutical industry is one of society’s biggest polluters, solving this challenge requires massive, cross-continent collaboration to spark real change. In this episode, we explore how some of the UK and Europe’s premier research institutes and pharmaceutical companies have joined forces to pioneer "greener" production methods. This work is funded by Horizon Europe, the European Union’s flagship €96 billion research and innovation funding programme. We visit Barcelona to talk to Dr Laura Rodriguez and Dr Andrés Cruz from IRIS Technology Solutions. They share how their collaboration with UK research teams has yielded impressive results—and why the partnership itself has been a key factor in the success. This is a New Scientist CoLab production, sponsored by the UK Government. For more information and to find a UK partner for your next Horizon Europe bid, click here. Your host is James Randerson. Read more about the UK-Spanish partnerships solving pharma’s toughest challenges. Learn more about your ad choices. Visit megaphone.fm/adchoices

For more than 35 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. These advances have transformed the outlook for people affected by HIV worldwide. In parallel, Gilead’s focus on catalytic collaborations at the global, national and local levels have helped to address the unmet needs of a wide range of individuals and communities. Jared Baeten is a physician, epidemiologist and head of R&D at Gilead Sciences who has spent decades working in partnership with collaborators around the world to help overcome the HIV epidemic. In this episode he discusses: The current landscape of HIV research Optionality and choice in HIV treatment and care Beyond the lab: education, access and barriers to care Achieving the collective vision of ending the HIV epidemic This podcast was created by our partner Gilead Sciences and produced by New Scientist CoLab. Hosted on Acast. See acast.com/privacy for more information. Learn more about your ad choices. Visit megaphone.fm/adchoices

Artificial Intelligence is revolutionising manufacturing and transforming the industrial world. From solving challenges thought unsolvable, to improving efficiency and sustainability, AI is a new type of industrial revolution that reduces energy usage and waste. And at its helm is global technology company Siemens.   Pina Schlombs is an expert on sustainability and AI at Siemens and in this episode she discusses: A robot gripper showcasing the power of industrial AI to solve complex engineering problems in a way that reduces their environmental impact. How industrial copilots are transforming the way we programme machines and generate product designs. How the logistics and carbon footprints of supply routes are being optimised with industrial AI. And why she’s optimistic this technology will help us achieve our ambitious net-zero goals.   This is a New Scientist CoLab production, sponsored by Siemens.   Your host is Justin Mullins. Find out more at newscientist.com/podcasts Hosted on Acast. See acast.com/privacy for more information. Learn more about your ad choices. Visit megaphone.fm/adchoices

As the UK transforms its ecosystem for clinical trials, the regulatory landscape is undergoing its biggest change in 20 years. In this third episode of this free New Scientist podcast, we meet Dr Melanie Ivarsson, from the global biotechnology company Moderna, to find out why she chose the UK for a billion-pound research and development program.   Sponsored by the UK Department for Business and Trade and the Medicines and Healthcare products Regulatory Agency Hosted on Acast. See acast.com/privacy for more information. Learn more about your ad choices. Visit megaphone.fm/adchoices

As the UK transforms its ecosystem for clinical trials, the regulatory landscape is undergoing its biggest change in 20 years. In this free New Scientist podcast, we meet Professor Andrea Manfrin whose team is responsible for driving this change at the Medicines and Healthcare products Regulatory Agency.    Sponsored by the UK Department for Business and Trade and the Medicines and Healthcare products Regulatory Agency Hosted on Acast. See acast.com/privacy for more information. Learn more about your ad choices. Visit megaphone.fm/adchoices

The UK has long been a world leader for clinical trials and life sciences research. But after losing ground post-COVID and post-Brexit, the country has begun to rethink the landscape for clinical trials. In this free New Scientist podcast, we meet the chair of the UK review into commercial clinical trials, James O'Shaughnessy, and ask how the independent review has influenced the reinvention of the clinical trials infrastructure for a new age of medicine. Sponsored by the UK Department for Business and Trade and the Medicines and Healthcare products Regulatory Agency Hosted on Acast. See acast.com/privacy for more information. Learn more about your ad choices. Visit megaphone.fm/adchoices

Imagine humans one day living and working on the ocean floor. Aquanauts in subsea habitats, surrounded by ocean creatures, discovering new secrets about our planet. This might sound like science fiction, but DEEP is already making this a reality. With the recent launch of its subsea habitat Vanguard, DEEP is pushing forward with its promise to make humans aquatic. An engineering company pushing the boundaries of what’s possible, DEEP exists to radically advance how humankind can access, explore and inhabit underwater environments. In this episode, Sophie Bushwick speaks to DEEP’s Chief Technology Officer, Norman Smith and Director of Habitat Operations, Roger Garcia. Together they take us on a tour of Vanguard, from its  cosy living area with a viewport to the ocean realm, to the “moon pool” which serves as the entryway into the habitat. They discuss the scientific missions a habitat like this enables - like planet-saving coral reef restoration. And they explore the engineering that’s gone into making this possible, the pressures and joys of life as an “aquanaut” and how it feels to have sea creatures as your neighbours. This is a New Scientist CoLab production, sponsored by DEEP. Your host is Sophie Bushwick. Find out more here. Learn more about your ad choices. Visit megaphone.fm/adchoices

The UK’s energy system is undergoing a quiet revolution. As we move away from fossil fuels towards a cleaner, more flexible, and electrified future, Octopus Energy is helping to turn the traditional power grid on its head. In this episode of New Scientist CoLab, Justin Mullins is joined by Kieron Stopforth, Head of Flexibility at Octopus Energy.  Kieron explains how the way we generate, store and use electricity is changing - and why your home, solar panels, and even your car could be part of the solution. This is a New Scientist CoLab production, sponsored by Octopus Energy. Your host is Justin Mullins. Find out more at newscientist.com/podcasts. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dementia is the UK’s leading cause of death, and one in three people born today will develop it in their lifetime. With numbers steadily rising, the need for effective treatments and improved dementia diagnosis is more urgent than ever. Thankfully, recent advances in science mean we understand the diseases that cause dementia better than ever. There has never been a more exciting time in dementia research, and supporting some of the most pioneering work in this field is UK charity Alzheimer’s Society. In this episode of the New Scientist CoLab podcast, Justin Mullins is joined by Richard Oakley, Associate Director of Research and Innovation at Alzheimer's Society. Richard explores the latest breakthroughs in dementia treatment and promising areas of research. He discusses the latest technologies and trials that are bringing us closer to a better future for people living with dementia. And he discusses his belief that research, with time, can beat dementia. This is a New Scientist CoLab production, sponsored by Alzheimer’s Society. Find out more at newscientist.com/podcasts Learn more about your ad choices. Visit megaphone.fm/adchoices